CHARCOAL - ACTIVATED; SODIUM NITRATE - search results

bluepoint laboratories - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 25 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets, usp and other treatment options before deciding to use diclofenac sodium delayed-release tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium delayed-release tablets, usp, are indicated: diclofenac sodium delayed-release tablets, are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings: anaphylactic reactions and precautions: preexisting asthma ). diclofenac sodium delayed-release tablets are contraindicated in the setting of coronary artery bypass graft (cabg) surgery (see warnings ).

United States - English - NLM (National Library of Medicine)

diclofenac sodium- diclofenac sodium gel

remedyrepack inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 30 mg in 1 g - diclofenac sodium gel, 3% is indicated for the topical treatment of actinic keratoses (ak). sun avoidance is indicated during therapy. diclofenac sodium gel, 3% is contraindicated in patients with a known hypersensitivity to diclofenac, benzyl alcohol and/or polyethylene glycol monomethyl ether 350. diclofenac sodium gel, 3% is contraindicated in the following patients: - in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

diclofenac sodium- diclofenac sodium solution

preferred pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 16.05 mg in 1 ml - diclofenac sodium topical solution is indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s) (1). diclofenac sodium topical solution is contraindicated in the following patients: pregnancy category c prior to 30 weeks gestation; category d starting 30 weeks gestation. risk summary use of nsaids, including diclofenac, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. avoid use of nsaids, including diclofenac, in pregnant women starting at 30 weeks of gestation (third trimester). there are no adequate and well-controlled studies of diclofenac sodium topical solution in pregnant women. data from observational studies regarding potential embryofetal risks of nsaid use in women in the first or second trimesters of pregnancy are inconclusive. in the general u.s. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations, and 15 to 20% for pregna